The nomination committee, which has been appointed for the time until a new nomination committee has been appointed, consists of three members, nominated by the Company’s three largest shareholders with respect to voting power as per 30 September 2024.

If a shareholder who previously appointed a member of the nomination committee during the year, appoints another member, the previous member must resign and the new member appointed.

Based on the above, the Nomination Committee for the AGM in 2025 consists of the following;

• Jens Segren, appointed by Systematic Group AB, the Company´s largest shareholder,
• Håkan Stödberg, the Company´s second largest shareholder and
• Bengt Göran Westman, the Company´s fifth largest shareholder
• Anders Tullgren, Chairman of the Board of the Company, co-opted member

In addition, Jens Segren, has been appointed Chairman of the Nomination Committee.

The task of the Nomination Committee is prior to AGM prepare and submit proposals regarding the Chairman of the AGM, candidates for the post of chairman and other directors of the board, fees, and other remuneration for board work to each director, fees to members of committees within the board, election and remuneration of the Company auditor and principles for the nomination committee. The Nomination Committee's proposal will be presented in the notice to the AGM 2025 and on the Company's website, www.xbrane.com.

Shareholders may submit proposals to the Nomination Committee for the AGM on May 5th, 2025, until January 20, 2025. The proposals can be sent to the following address: Xbrane Biopharma AB Nomination Committee, c/o Xbrane Biopharma AB, Retzius väg 8, 171 65 Solna, Sweden, or via email: valberedning@xbrane.com.

The Annual General Meeting will be held in Stockholm on May 5th, 2025.